Protara Therapeutics CMO Departs; Jathin Bandari Named Interim CMO

Protara Therapeutics, Inc.

Martín Sebastian Olivo, M.D., left as Chief Medical Officer effective Oct 15, 2021; will serve as consultant through Nov 22, 2021.
Jathin Bandari, M.D., promoted to VP, Head of Clinical Development and Interim Chief Medical Officer.
Severance includes nine months base salary lump sum, pro-rata bonus, COBRA reimbursement, and pro-rata equity vesting.
Dr. Bandari joined Protara in April 2020; is a urologic oncologist with fellowship at University of Pittsburgh Medical Center.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Martín Sebastian Olivo

Chief Medical Officer

TARA · Protara Therapeutics, Inc.

Effective: 2021-10-15
Filed: October 18, 2021, 7:59 PM ET

Effective October 15, 2021, Martín Sebastian Olivo, M.D. will no longer be employed by the Company as Chief Medical Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martín Sebastian Olivo departed as Chief Medical Officer at Protara Therapeutics, Inc..

Action: will no longer be employed
Role: Chief Medical Officer

Exact text from the filing

Effective October 15, 2021, Martín Sebastian Olivo, M.D. will no longer be employed by the Company as Chief Medical Officer

View on SEC.gov

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-21-053303

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.